First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients

Statistical parametric maps in functional imaging: A general linear approach

Friston, K. J., Holmes, A. P., Worsley, K. J., Poline, J. ‐., Frith, C. D., & Frackowiak, R. S. J. (1994) · Human Brain Mapping · doi:10.1002/hbm.460020402 · Cited by 9,688

Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia

Coyle, J. T., Tsai, G. E., & GOFF, D. C. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.020 · Cited by 443

Usefulness of a three-dimensional stereotaxic ROI template on anatomically standardised 99mTc-ECD SPET

Takeuchi, R., Yonekura, Y., Matsuda, H., & Konishi, J. (2002) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-001-0715-z · Cited by 134

Impact of Schizophrenia and Chronic Antipsychotic Treatment on [123I]CNS-1261 Binding to N-Methyl-D-Aspartate Receptors In Vivo

Bressan, R. A., Erlandsson, K., Stone, J. M., Mulligan, R. S., Krystal, J. H., Ell, P. J., & Pilowsky, L. S. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.03.016 · Cited by 57

Kinetic modelling of [123I]CNS 1261—a potential SPET tracer for the NMDA receptor

Erlandsson, K., Bressan, R. A., Mulligan, R. S., Gunn, R. N., Cunningham, V. J., Owens, J., Wyper, D. J., Ell, P. J., & Pilowsky, L. S. (2003) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(02)00450-x · Cited by 40

Untitled work

Lurito (2000) · doi:10.1002/1097-0193(200007)10:3

Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment

McCutcheon, R. A., Keefe, R. S. E., & McGuire, P. K. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-01949-9 · Cited by 861

A critical role for NMDA receptors in parvalbumin interneurons for gamma rhythm induction and behavior

Carlén, M., Meletis, K., Siegle, J. H., Cardin, J. A., Futai, K., Vierling-Claassen, D., Rühlmann, C., Jones, S. R., Deisseroth, K., Sheng, M., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.31 · Cited by 669

Glutamate and dopamine in schizophrenia: An update for the 21 st century

Howes, O., McCutcheon, R., & Stone, J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114563634 · Cited by 702

The Hippocampal Formation in Schizophrenia

Tamminga, C. A., Stan, A. D., & Wagner, A. D. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09081187 · Cited by 597

Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions

Schaefer, G. B., & Mendelsohn, N. J. (2013) · Genetics in Medicine · doi:10.1038/gim.2013.32 · Cited by 537

A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy

Norberg, M. M., Krystal, J. H., & Tolin, D. F. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.01.012 · Cited by 510

GABAergic Interneurons Shape the Functional Maturation of the Cortex

Le Magueresse, C., & Monyer, H. (2013) · Neuron · doi:10.1016/j.neuron.2013.01.011 · Cited by 425

Disrupted-in-Schizophrenia 1 (DISC1) regulates spines of the glutamate synapse via Rac1

Hayashi-Takagi, A., Takaki, M., Graziane, N., Seshadri, S., Murdoch, H., Dunlop, A. J., Makino, Y., Seshadri, A. J., Ishizuka, K., Srivastava, D. P., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2487 · Cited by 399

Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology

Kaar, S. J., Natesan, S., McCutcheon, R. A., & Howes, O. D. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107704 · Cited by 404

Glutamate hypothesis in schizophrenia

Uno, Y., & Coyle, J. T. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12823 · Cited by 389

The Neuregulin-1 Receptor ErbB4 Controls Glutamatergic Synapse Maturation and Plasticity

Li, B., Woo, R.-S., Mei, L., & Malinow, R. (2007) · Neuron · doi:10.1016/j.neuron.2007.03.028 · Cited by 354

Review: Glutamate and dopamine dysregulation in schizophrenia — a synthesis and selective review

Stone, J. M., Morrison, P. D., & Pilowsky, L. S. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106073126 · Cited by 362

Models of schizophrenia in humans and animals based on inhibition of NMDA receptors

Bubeníková‐Valešová, V., Horáček, J., Vrajová, M., & Höschl, C. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.03.012 · Cited by 346

N-Methyl d-Aspartate Receptor Antagonists Ketamine and MK-801 Induce Wake-Related Aberrant γ Oscillations in the Rat Neocortex

Pinault, D. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.10.006 · Cited by 315

Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis

Hardingham, G. E., & Do, K. Q. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.19 · Cited by 304

Reviewing the ketamine model for schizophrenia

Frohlich, J., & Van Horn, J. D. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113512909 · Cited by 303

Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment

Chaudhry, I. B., Hallak, J. E. C., Husain, N., Minhas, F., Stirling, J., Richardson, P., Dursun, S. M., Dunn, G., & Deakin, J. F. W. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444941 · Cited by 284

The Role of Memantine in the Treatment of Psychiatric Disorders Other Than the Dementias: A Review of Current Preclinical and Clinical Evidence

Sani, G., Serra, G., Kotzalidis, G. D., Romano, S., Tamorri, S. M., Manfredi, G., Caloro, M., Telesforo, C. L., Caltagirone, S. S., Panaccione, I., et al. (2012) · CNS Drugs · doi:10.2165/11634390-000000000-00000 · Cited by 273

Excitation, inhibition, local oscillations, or large-scale loops: what causes the symptoms of schizophrenia?

Lisman, J. E. (2011) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2011.10.018 · Cited by 279

Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume

Stone, J. M., Day, F., Tsagaraki, H., Valli, I., McLean, M. A., Lythgoe, D. J., O'Gorman, R. L., Barker, G. J., & McGuire, P. K. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.05.006 · Cited by 231

Rare mutations in N-methyl-D-aspartate glutamate receptors in autism spectrum disorders and schizophrenia

Tarabeux, J., Kebir, O., Gauthier, J., Hamdan, F. F., Xiong, L., Piton, A., Spiegelman, D., Henrion, É., Millet, B., S2D team, et al. (2011) · Translational Psychiatry · doi:10.1038/tp.2011.52 · Cited by 231

Brain NMDA Receptors in Schizophrenia and Depression

Adell, A. (2020) · Biomolecules · doi:10.3390/biom10060947 · Cited by 225

Cerebello-thalamo-cortical hyperconnectivity as a state-independent functional neural signature for psychosis prediction and characterization

Cao, H., Chén, O. Y., Chung, Y., Forsyth, J. K., McEwen, S. C., Gee, D. G., Bearden, C. E., Addington, J., Goodyear, B., Cadenhead, K. S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06350-7 · Cited by 211

Imaging glutamate in schizophrenia: review of findings and implications for drug discovery

Poels, E. M. P., Kegeles, L. S., Kantrowitz, J. T., Slifstein, M., Javitt, D. C., Lieberman, J. A., Abi-Dargham, A., & Girgis, R. R. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.136 · Cited by 205

Schizophrenia: from neurochemistry to circuits, symptoms and treatments

Howes, O. D., Bukala, B. R., & Beck, K. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00904-0 · Cited by 221

Meta-Analysis of the Efficacy of Adjunctive NMDA Receptor Modulators in Chronic Schizophrenia

Singh, S. P., & Singh, V. (2011) · CNS Drugs · doi:10.2165/11586650-000000000-00000 · Cited by 194

Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists

Krystal, J. H., Mathew, S. J., DʼSouza, D. C., Garakani, A., Gunduz-Bruce, H., & Charney, D. S. (2010) · CNS Drugs · doi:10.2165/11533230-000000000-00000 · Cited by 180

MicroRNA dysregulation in psychiatric disease

Miller, B. H., & Wahlestedt, C. (2010) · Brain Research · doi:10.1016/j.brainres.2010.03.035 · Cited by 185

Influence of the NR3A subunit on NMDA receptor functions

Henson, M. A., Roberts, A. C., Pérez‐Otaño, I., & Philpot, B. D. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.01.004 · Cited by 195

Copy number variations associated with autism spectrum disorders contribute to a spectrum of neurodevelopmental disorders

Rosenfeld, J. A., Ballif, B. C., Torchia, B. S., Sahoo, T., Ravnan, J. B., Schultz, R., Lamb, A., Bejjani, B. A., & Shaffer, L. G. (2010) · Genetics in Medicine · doi:10.1097/gim.0b013e3181f0c5f3 · Cited by 169

Using large clinical data sets to infer pathogenicity for rare copy number variants in autism cohorts

Moreno-De-Luca, D., Sanders, S. J., Willsey, A. J., Mulle, J. G., Lowe, J. K., Geschwind, D. H., State, M. W., Martin, C. L., & Ledbetter, D. H. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.138 · Cited by 161

Region-Specific Changes in Gamma and Beta2 Rhythms in NMDA Receptor Dysfunction Models of Schizophrenia

Roopun, A. K., Cunningham, M. O., Racca, C., Alter, K., Traub, R. D., & Whittington, M. A. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn059 · Cited by 165

Schizophrenia susceptibility pathway neuregulin 1–ErbB4 suppresses Src upregulation of NMDA receptors

Pitcher, G. M., Kalia, L. V., Ng, D., Goodfellow, N. M., Yee, K. T., Lambe, E. K., & Salter, M. W. (2011) · Nature Medicine · doi:10.1038/nm.2315 · Cited by 164

Glutamatergic Dysfunction and Glutamatergic Compounds for Major Psychiatric Disorders: Evidence From Clinical Neuroimaging Studies

Li, C., Yang, K., & Lin, W. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00767 · Cited by 180

Functional neuroimaging in schizophrenia: diagnosis and drug discovery

McGuire, P. K., Howes, O. D., Stone, J. M., & Fusar‐Poli, P. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.11.005 · Cited by 157

Glutamate signaling in the pathophysiology and therapy of schizophrenia

Lin, C., Lane, H., & Tsai, G. E. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.03.023 · Cited by 154

Glutamatergic dysfunction in Schizophrenia

Kruse, A. O., & Bustillo, J. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02253-w · Cited by 162

GABA and glutamate in schizophrenia: A 7 T 1H-MRS study

Marsman, A., Mandl, R. C. W., Klomp, D. W. J., Bohlken, M. M., Boer, V. O., Андрейченко, А. Е., Cahn, W., Kahn, R. S., Luijten, P. R., & Pol, H. E. H. (2014) · NeuroImage Clinical · doi:10.1016/j.nicl.2014.10.005 · Cited by 159

Glutamate-mediated excitotoxicity in schizophrenia: A review

Plitman, E., Nakajima, S., de la Fuente‐Sandoval, C., Gerretsen, P., Chakravarty, M. M., Kobylianskii, J., Chung, J. K., Caravaggio, F., Iwata, Y., Remington, G. J., et al. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.07.015 · Cited by 150

Genetics of autism spectrum disorders

Kumar, R. A., & Christian, S. L. (2009) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-009-0029-2 · Cited by 150

Oxidative Stress and the Pathophysiology and Symptom Profile of Schizophrenia Spectrum Disorders

Murray, A., Rogers, J. C., Katshu, M. Z. U. H., Liddle, P. F., & Upthegrove, R. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.703452 · Cited by 152

GluN3 subunit-containing NMDA receptors: not just one-trick ponies

Pachernegg, S., Strutz‐Seebohm, N., & Hollmann, M. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2011.11.010 · Cited by 162

Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia

Labrie, V., Lipina, T. V., & Roder, J. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1196-6 · Cited by 141

Is the Acute NMDA Receptor Hypofunction a Valid Model of Schizophrenia?

Adell, A., Jiménez-Sánchez, L., López-Gil, X., & Romón, T. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr133 · Cited by 142

Glutamate-Mediated Excitotoxicity in the Pathogenesis and Treatment of Neurodevelopmental and Adult Mental Disorders

Nicosia, N., Giovenzana, M., Misztak, P., Mingardi, J., & Musazzi, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126521 · Cited by 135

Drug models of schizophrenia

Steeds, H., Carhart-Harris, R. L., & Stone, J. M. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314557797 · Cited by 143

Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis.

Stone, J., Howes, O., Egerton, A., Kambeitz, J., Allen, P., Lythgoe, D., O'Gorman, R., McLean, M., Barker, G., & McGuire, P. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.05.034 · Cited by 151

Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-d-aspartic acid receptor up-regulation

Gray, L., van den Buuse, M., Scarr, E., Dean, B., & Hannan, A. J. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009085 · Cited by 130

Proton Magnetic Resonance Spectroscopy and Illness Stage in Schizophrenia—A Systematic Review and Meta-Analysis

Brugger, S., Davis, J. M., Leucht, S., & Stone, J. M. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.10.004 · Cited by 131

Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics

Lally, J., Gaughran, F., Timms, P. W., & Curran, S. R. (2016) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s115741 · Cited by 133

In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders

Nikolaus, S., Antke, C., & Müller, H. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.06.009 · Cited by 128

Inhibition of NMDARs in the nucleus reticularis of the thalamus produces delta frequency bursting

Zang, Y. (2009) · Frontiers in Neural Circuits · doi:10.3389/neuro.04.020.2009 · Cited by 127

Contributions of the d-serine pathway to schizophrenia

Labrie, V., Wong, A. H. C., & Roder, J. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.030 · Cited by 121

The involvement of the NMDA receptor d-serine/glycine site in the pathophysiology and treatment of schizophrenia

Labrie, V., & Roder, J. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.08.002 · Cited by 118

A Thalamo-Hippocampal-Ventral Tegmental Area Loop May Produce the Positive Feedback that Underlies the Psychotic Break in Schizophrenia

Lisman, J. E., Pi, H. J., Zhang, Y., & Otmakhova, N. A. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.04.007 · Cited by 123

The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view

Müller, N., & Schwarz, M. (2007) · Springer eBooks · doi:10.1007/978-3-211-73574-9_33 · Cited by 107

Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy—a [123I]CNS-1261 SPET study

Stone, J. M., Erlandsson, K., Arstad, E., Squassante, L., Teneggi, V., Bressan, R. A., Krystal, J. H., Ell, P. J., & Pilowsky, L. S. (2008) · Psychopharmacology · doi:10.1007/s00213-007-1047-x · Cited by 103

Positive Allosteric Modulation of Metabotropic Glutamate 5 (mGlu5) Receptors Reverses N-Methyl-D-Aspartate Antagonist-Induced Alteration of Neuronal Firing in Prefrontal Cortex

Lecourtier, L., Homayoun, H., Tamagnan, G. D., & Moghaddam, B. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.12.003 · Cited by 103

Relationship between Glutamate Dysfunction and Symptoms and Cognitive Function in Psychosis

Merritt, K., McGuire, P. K., & Egerton, A. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00151 · Cited by 100

Neurosteroid Actions in Memory and Neurologic/Neuropsychiatric Disorders

Ratner, M. H., Kumaresan, V., & Farb, D. H. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00169 · Cited by 96

Does the dopamine hypothesis explain schizophrenia?

Lau, C. I., Wang, H.-C., Hsu, J.-L., & Liu, M. (2013) · Reviews in the Neurosciences · doi:10.1515/revneuro-2013-0011 · Cited by 102

NMDA Receptor Internalization by Autoantibodies: A Reversible Mechanism Underlying Psychosis?

Masdeu, J. C., Dalmau, J. O., & Berman, K. F. (2016) · Trends in Neurosciences · doi:10.1016/j.tins.2016.02.006 · Cited by 92

Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia

Fell, M. J., McKinzie, D. L., Monn, J. A., & Svensson, K. A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.06.007 · Cited by 90

Cannabidiol attenuates sensorimotor gating disruption and molecular changes induced by chronic antagonism of NMDA receptors in mice

Gomes, F. V., Issy, A. C., Ferreira, F. R., Viveros, M.-P., Del Bel, E. A., & Guimarães, F. S. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu041 · Cited by 89

Metabotropic Glutamate Receptors as Therapeutic Targets for Schizophrenia

Vinson, P., & Conn, P. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.05.005 · Cited by 95

Syndromic autism: causes and pathogenetic pathways

Benvenuto, A., Moavero, R., Alessandrelli, R., Manzi, B., & Curatolo, P. (2009) · World Journal of Pediatrics · doi:10.1007/s12519-009-0033-2 · Cited by 93

Activation Mechanisms of the NMDA Receptor

Blanke, M. L., & VanDongen, A. M. J. (2009) · Europe PMC (PubMed Central) · Cited by 89

Relationship between brain glutamate levels and clinical outcome in individuals at ultra high risk of psychosis

Egerton, A., Stone, J., Chaddock, C. A., Barker, G., Bonoldi, I., Howard, R. M., Merritt, K., Allen, P., Howes, O., Murray, R., et al. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.143 · Cited by 94

Neurochemical changes in the rat prefrontal cortex following acute phencyclidine treatment: an in vivo localized 1H MRS study

Iltis, I., Koski, D. M., Eberly, L. E., Nelson, C. D., Deelchand, D. K., Valette, J., Uǧurbil, K., Lim, K. O., & Henry, P. (2009) · NMR in Biomedicine · doi:10.1002/nbm.1385 · Cited by 83

The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia

Krystal, J. H., D’Souza, D. C., Gallinat, J., Driesen, N. R., Abi‐Dargham, A., Petrakis, I. L., Heinz, A., & Pearlson, G. D. (2006) · Neurotoxicity Research · doi:10.1007/bf03033360 · Cited by 87

Neurobiological basis of motivational deficits in psychopathology

Salamone, J. D., Koychev, I. G., Correa, M., & McGuire, P. K. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.08.014 · Cited by 87

Increased Glutamine in Patients Undergoing Long-term Treatment for Schizophrenia

Bustillo, J., Chen, H., Jones, T., Lemke, N. T., Abbott, C., Qualls, C., Cañive, J. M., & Gasparovic, C. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.3939 · Cited by 82

Antibodies to the N-Methyl-D-Aspartate Receptor and Other Synaptic Proteins in Psychosis

Deakin, J., Lennox, B., & Zandi, M. S. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.07.018 · Cited by 81

Peripheral Biomarkers Revisited: Integrative Profiling of Peripheral Samples for Psychiatric Research

Hayashi‐Takagi, A., Vawter, M. P., & Iwamoto, K. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.09.035 · Cited by 82

Impaired prefrontal synaptic gain in people with psychosis and their relatives during the mismatch negativity

Ranlund, S., Adams, R. A., Díez, Á., Constante, M., Dutt, A., Hall, M., Maestro Carbayo, A., McDonald, C., Petrella, S., Schulze, K., et al. (2016) · Human Brain Mapping · doi:10.1002/hbm.23035 · Cited by 77

Glutamate Networks Implicate Cognitive Impairments in Schizophrenia: Genome-Wide Association Studies of 52 Cognitive Phenotypes

Ohi, K., Hashimoto, R., Ikeda, M., Yamamori, H., Yasuda, Y., Fujimoto, M., Umeda‐Yano, S., Fukunaga, M., Fujino, H., Watanabe, Y., et al. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu171 · Cited by 77

Dissection of phenotype reveals possible association between schizophrenia and Glutamate Receptor Delta 1 (GRID1) gene promoter

Treutlein, J., Mühleisen, T. W., Frank, J., Mattheisen, M., Herms, S., Ludwig, K. U., Treutlein, T. L., Schmael, C., Strohmaier, J., Böhenz, K. V., et al. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.03.011 · Cited by 80

ErbB4 is a suppressor of long-term potentiation in the adult hippocampus

Pitcher, G. M., Beggs, S., Woo, R., Mei, L., & Salter, M. W. (2008) · Neuroreport · doi:10.1097/wnr.0b013e3282f3da10 · Cited by 75

Mapping prodromal psychosis: A critical review of neuroimaging studies

Fusar‐Poli, P., McGuire, P. K., & Borgwardt, S. (2011) · European Psychiatry · doi:10.1016/j.eurpsy.2011.06.006 · Cited by 75

Schizophrenia‐related endophenotypes in heterozygous neuregulin‐1 ‘knockout’ mice

O’Tuathaigh, C. M. P., Harte, M., O’Leary, C., O'Sullivan, G., Blau, C., Lai, D., Harvey, R. P., Tighe, O., Fagan, A. J., Kerskens, C., et al. (2010) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.07069.x · Cited by 76

Mutant mice with reduced NMDA-NR1 glycine affinity or lack of d-amino acid oxidase function exhibit altered anxiety-like behaviors

Labrie, V., Clapcote, S. J., & Roder, J. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.09.016 · Cited by 73

Clinical management of negative symptoms of schizophrenia: An update

Tsapakis, E.-M., Dimopoulou, T., & Tarazi, F. I. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.06.008 · Cited by 76

Autoantibodies to central nervous system neuronal surface antigens: psychiatric symptoms and psychopharmacological implications

Pollak, T. A., Beck, K., Irani, S. R., Howes, O. D., David, A. S., & McGuire, P. K. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4156-y · Cited by 72

Mutant Mouse Models: Genotype-Phenotype Relationships to Negative Symptoms in Schizophrenia

O’Tuathaigh, C. M. P., Kirby, B. P., Moran, P. M., & Waddington, J. L. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp125 · Cited by 73

Imaging-Based Neurochemistry in Schizophrenia: A Systematic Review and Implications for Dysfunctional Long-Term Potentiation

Salavati, B., Rajji, T. K., Price, R., Sun, Y., Graff‐Guerrero, A., & Daskalakis, Z. J. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu132 · Cited by 71

Neuroimmune–endocrine crosstalk in schizophrenia and mood disorders

Müller, N., & Schwarz, M. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.7.1017 · Cited by 70

Dynamic Regulation of Glutamatergic Postsynaptic Activity in Rat Prefrontal Cortex by Repeated Administration of Antipsychotic Drugs

Fumagalli, F., Frasca, A., Racagni, G., & Riva, M. A. (2008) · Molecular Pharmacology · doi:10.1124/mol.107.043786 · Cited by 66

Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment

Ellaithy, A., Younkin, J., González‐Maeso, J., & Logothetis, D. E. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2015.06.002 · Cited by 64

Hippocampal circuit dysfunction in psychosis

Knight, S., McCutcheon, R. A., Dwir, D., Grace, A. A., O’Daly, O., McGuire, P. K., & Modinos, G. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02115-5 · Cited by 61

Activation Mechanisms of the NMDA Receptor

VanDongen, A. M. J., & Blanke, M. L. (2008) · Frontiers in neuroscience · doi:10.1201/9781420044157.ch13 · Cited by 61

Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia?

Stone, J. M. (2011) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125311400779 · Cited by 60

A Review of Molecular Imaging of Glutamate Receptors

Kim, J., Marton, J., Ametamey, S. M., & Cumming, P. D. (2020) · Molecules · doi:10.3390/molecules25204749 · Cited by 60

Altered medial temporal activation related to local glutamate levels in subjects with prodromal signs of psychosis.

Valli, I., Stone, J., Mechelli, A., Bhattacharyya, S., Raffin, M., Allen, P., Fusar-Poli, P., Lythgoe, D., O'Gorman, R., Seal, M., et al. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.033 · Cited by 72

Postsynaptic density levels of the NMDA receptor NR1 subunit and PSD-95 protein in prefrontal cortex from people with schizophrenia

Catts, V. S., Derminio, D. S., Hahn, C.-G., & Weickert, C. S. (2015) · npj Schizophrenia · doi:10.1038/npjschz.2015.37 · Cited by 58

Switching schizophrenia patients from typical neuroleptics to olanzapine: Effects on BOLD response during attention and working memory

Schlagenhauf, F., Wüstenberg, T., Schmack, K., Dinges, M., Wrase, J., Koslowski, M., Kienast, T., Bauer, M., Gallinat, J., Juckel, G., et al. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.04.013 · Cited by 57

Transient blockade of ERK phosphorylation in the critical period causes autistic phenotypes as an adult in mice

Yufune, S., Satoh, Y., Takamatsu, I., Ohta, H., Kobayashi, Y., Takaenoki, Y., Pagès, G., Pouysségur, J., Endo, S., & Kazama, T. (2015) · Scientific Reports · doi:10.1038/srep10252 · Cited by 57

Mice mutant for genes associated with schizophrenia: Common phenotype or distinct endophenotypes?

Desbonnet, L., Waddington, J. L., & O’Tuathaigh, C. M. P. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.04.001 · Cited by 57

What is new in autism?

Rapin, I., & Tuchman, R. F. (2008) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3282f49579 · Cited by 57

Phencyclidine and Dizocilpine Induced Behaviors Reduced by N-acetylaspartylglutamate Peptidase Inhibition via Metabotropic Glutamate Receptors

Olszewski, R. T., Wegorzewska, M. M., Monteiro, A. C., Krolikowski, K. A., Zhou, J., Kozikowski, A. P., Long, K. D., Mastropaolo, J. P., Deutsch, S. I., & Neale, J. H. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.04.016 · Cited by 56

Mutant models for genes associated with schizophrenia

Desbonnet, L., Waddington, J. L., & O’Tuathaigh, C. M. P. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370308 · Cited by 57

Mnemonic Discrimination Deficits in First-Episode Psychosis and a Ketamine Model Suggest Dentate Gyrus Pathology Linked to NMDA Receptor Hypofunction

Kraguljac, N. V., Carle, M. S., Frölich, M. A., Tran, S., Yassa, M. A., White, D. M., Reddy, A., & Lahti, A. C. (2021) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2021.09.008 · Cited by 12

Long-lasting changes in hippocampal synaptic plasticity and cognition in an animal model of NMDA receptor dysfunction in psychosis

Wiescholleck, V., & Manahan‐Vaughan, D. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.01.001 · Cited by 54

N-Methyl-D-Aspartate Receptor binding in First-Episode Psychosis: A PET brain imaging study

Beck, K., Arumuham, A., Santangelo, B., Veronese, M., McCutcheon, R. A., Kaar, S. J., McGinnity, C. J., Pillinger, T., Borgan, F., Hammers, A., et al. (2021) · BJPsych Open · doi:10.1192/bjo.2021.79 · Cited by 1

The association between N-methyl-d-aspartate receptor availability and glutamate levels: A multi-modal PET-MR brain imaging study in first-episode psychosis and healthy controls

Beck, K., Arumuham, A., Brugger, S., McCutcheon, R., Veronese, M., Santangelo, B., McGinnity, C., Dunn, J., Kaar, S., Singh, N., et al. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221099643 · Cited by 6

A Pharmacological Model for Psychosis Based on N-methyl-D-aspartate Receptor Hypofunction: Molecular, Cellular, Functional and Behavioral Abnormalities

Rujescu, D., Bender, A., Keck, M. E., Hartmann, A. M., Ohl, F., Ræder, H., Giegling, I., Genius, J., McCarley, R. W., Möller, H., et al. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.08.029 · Cited by 241